SIGA Technologies Logo
US8269171067
919473
SIGA

SIGA Technologies

Prévisions

Acheter
  1
Conserver
  0
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • SIGA Technologies pays special dividend of $0.60 per share

    The board of directors of SIGA Technologies has approved a cash dividend of $0.60 per common share, payable on April 23, 2026 to shareholders of record at the close of trading on April 7, 2026. The payout matches the special dividend announced in April 2025 and, according to InvestingPro, represents a yield of about 12%. The company shows a high liquidity ratio (current ratio 11.83), while the stock, at $4.81, is trading near its 52-week low and has fallen roughly 46% over the past six months. SIGA Technologies is in the commercialization phase and focuses on drugs for the treatment and prevention of infectious diseases, particularly orthopoxviruses. » Plus sur de.investing.com


  • SIGA Technologies posts annual profit of $23 million despite quarterly loss

    SIGA Technologies reported 2025 annual revenue of $95 million and a net profit of $23 million, with a cash balance of $155 million and no debt. However, in the fourth quarter the company posted a loss per share of -$0.08, highlighting quarterly volatility due to irregular government procurement. Investor reactions were mixed: the stock fell in after-hours trading but recovered in pre-market trading. Remaining risks include regulatory uncertainty in Europe for the Mpox indication and strong dependence on U.S. government contracts. » Plus sur de.investing.com


  • SIGA Technologies reports strong 2025 results and remains debt-free

    SIGA Technologies recorded total revenue of $95 million in 2025, including $88 million in product revenue, and net income of $23 million (earnings per share $0.32). The company holds $155 million in cash, is debt-free, and delivered TPOXX worth $79 million to the U.S. government. Outstanding government orders of $26 million for 2026, plus $27 million in grants for pediatric and intravenous formulations, underpin the optimistic outlook. » Plus sur de.investing.com


  • SIGA Technologies: stock falls despite strong revenue growth in third quarter

    SIGA Technologies reported product revenues of $86 million for the first nine months (prior year $54 million), driven by strong TPOXX sales. The company holds $172 million in cash and is debt-free; net income for the nine months amounted to $29 million. The stock fell 3.08% to $8.07 in after-hours trading following the release of the figures. SIGA plans an FDA filing for TPOXX for post-exposure prophylaxis, is working on a pediatric formulation and expects international sales in 2026, but sees risks from procurement delays and regulatory hurdles. » Plus sur de.investing.com


  • SIGA Technologies reports stable quarterly results and remains financially solid

    SIGA Technologies posted stable revenues of $79 million and earnings per share of $0.49 in the second quarter of 2025, while the stock price remained nearly unchanged. The company remains debt-free with a cash balance of $182 million and plans to submit new approval applications for its TPOXX products. However, international business development remains volatile, and reliance on US government contracts poses risks. » Plus sur de.investing.com

En 2026, SIGA Technologies a déjà versé 0,51 € de dividendes. Le dernier versement a eu lieu en avril.

Données financières

Au dernier trimestre, SIGA Technologies a réalisé un chiffre d'affaires de 1,16 M € et un bénéfice net de -2,55 M €

(EUR) septembre 2026
YoY
Chiffre d'affaires 1,16 M 47,92 %
Bénéfice brut 654,46 k 52,53 %
Bénéfice net -2,55 M 52,91 %
EBITDA -4,84 M 30,85 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
156,84 M €
Nombre d'actions
71,86 M
Plus haut/bas sur 52 semaines
6,48 € - 2,16 €
Rendement du dividende
19,83 %
Dividendes TTM
0,51 €
Bêta
1,02
Ratio P/E
374,22
Ratio PEG
-3,43
Ratio P/B
1,05
Ratio P/S
3,29

Profil de l'entreprise

SIGA Technologies, Inc., une entreprise pharmaceutique en phase de commercialisation, se concentre sur les marchés de la sécurité sanitaire et des maladies infectieuses aux États-Unis. Son produit phare est le TPOXX, un antiviral par voie orale destiné au traitement de la variole humaine causée par le virus variola. SIGA Technologies, Inc. a noué un partenariat stratégique avec Cipla Therapeutics afin d'assurer une innovation durable et l'accès à des médicaments antibactériens, principalement contre les menaces biologiques. La société a été constituée en 1995 et son siège social se situe à New York, New York.

Nom
SIGA Technologies
PDG
Diem Nguyen
Siège social New York City, ny
États-Unis
Site web
Secteur
Matériaux
Industrie
Produits chimiques
Introduction en bourse
10/09/1997
Employés 49

Symboles boursiers

Bourse Symbole
NASDAQ
SIGA
🍪

Parqet  utilise des cookies. En savoir plus